The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Recruiting · NCT03878706 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Athens
View the official record on ClinicalTrials.gov →What this trial is about
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.
Who can take part
Inclusion criteria
- Subject has type 2 diabetes mellitus
- Subject has high or very high cardiovascular risk
- Subject has heart failure with preserved ejection fraction
Exclusion criteria
- Subject has type 1 diabetes mellitus
- Subject has kidney disease
- Subject has retinopathy
Where it is running
1 location listed.
- "Attikon" University General Hospital - Athens, Attica, Greece